These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22331615)

  • 1. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation.
    Diamond DL; Krasnoselsky AL; Burnum KE; Monroe ME; Webb-Robertson BJ; McDermott JE; Yeh MM; Dzib JF; Susnow N; Strom S; Proll SC; Belisle SE; Purdy DE; Rasmussen AL; Walters KA; Jacobs JM; Gritsenko MA; Camp DG; Bhattacharya R; Perkins JD; Carithers RL; Liou IW; Larson AM; Benecke A; Waters KM; Smith RD; Katze MG
    Hepatology; 2012 Jul; 56(1):28-38. PubMed ID: 22331615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems biology methods help develop a better understanding of hepatitis C virus-induced liver injury.
    Singaravelu R; Nasheri N; Sherratt A; Pezacki JP
    Hepatology; 2012 Jul; 56(1):1-4. PubMed ID: 22430896
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients.
    Smith MW; Walters KA; Korth MJ; Fitzgibbon M; Proll S; Thompson JC; Yeh MM; Shuhart MC; Furlong JC; Cox PP; Thomas DL; Phillips JD; Kushner JP; Fausto N; Carithers RL; Katze MG
    Gastroenterology; 2006 Jan; 130(1):179-87. PubMed ID: 16401481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
    Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation.
    Joshi D; Salehi S; Brereton H; Arno M; Quaglia A; Heaton N; O'Grady J; Agarwal K; Aluvihare V
    Liver Transpl; 2013 Apr; 19(4):383-94. PubMed ID: 23408392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M; Aguilera V; Prieto M; Carrasco D; Rayón M; San Juan F; Landaverde C; Mir J; Berenguer J
    Liver Transpl; 2003 Nov; 9(11):1152-8. PubMed ID: 14586875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation.
    Gehrau RC; Mas VR; Villamil FG; Dumur CI; Mehta NK; Suh JL; Maluf DG
    Am J Transplant; 2013 Mar; 13(3):729-37. PubMed ID: 23312020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation.
    Mas V; Maluf D; Archer KJ; Potter A; Suh J; Gehrau R; Descalzi V; Villamil F
    Liver Transpl; 2011 Jul; 17(7):824-35. PubMed ID: 21618696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
    Brandman D; Pingitore A; Lai JC; Roberts JP; Ferrell L; Bass NM; Terrault NA
    Liver Transpl; 2011 Dec; 17(12):1380-6. PubMed ID: 21770018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction.
    Diamond DL; Jacobs JM; Paeper B; Proll SC; Gritsenko MA; Carithers RL; Larson AM; Yeh MM; Camp DG; Smith RD; Katze MG
    Hepatology; 2007 Sep; 46(3):649-57. PubMed ID: 17654742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
    Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
    Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
    Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are posttransplantation protocol liver biopsies useful in the long term?
    Berenguer M; Rayón JM; Prieto M; Aguilera V; Nicolás D; Ortiz V; Carrasco D; López-Andujar R; Mir J; Berenguer J
    Liver Transpl; 2001 Sep; 7(9):790-6. PubMed ID: 11552213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.
    Gallegos-Orozco JF; Yosephy A; Noble B; Aqel BA; Byrne TJ; Carey EJ; Douglas DD; Mulligan D; Moss A; de Petris G; Williams JW; Rakela J; Vargas HE
    Liver Transpl; 2009 Dec; 15(12):1872-81. PubMed ID: 19938138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteome analysis of liver cells expressing a full-length hepatitis C virus (HCV) replicon and biopsy specimens of posttransplantation liver from HCV-infected patients.
    Jacobs JM; Diamond DL; Chan EY; Gritsenko MA; Qian W; Stastna M; Baas T; Camp DG; Carithers RL; Smith RD; Katze MG
    J Virol; 2005 Jun; 79(12):7558-69. PubMed ID: 15919910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients.
    Lee VS; Miller FH; Omary RA; Wang Y; Ganger DR; Wang E; Rao S; Levitsky J
    Transplantation; 2011 Sep; 92(5):581-6. PubMed ID: 21822174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression.
    Delladetsima I; Psichogiou M; Sypsa V; Sakellariou S; Hatzakis A; N Boletis J
    Clin Transplant; 2013; 27(1):72-9. PubMed ID: 22994949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.